Title : Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.

Pub. Date : 2015 Aug

PMID : 26133921






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This study investigates whether combining all-trans retinoic acid (ATRA) and histone deacetylase inhibitor entinostat (ENT) can inhibit TICs and HER2 in AI-resistant cells and tumors. Tretinoin erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 This study investigates whether combining all-trans retinoic acid (ATRA) and histone deacetylase inhibitor entinostat (ENT) can inhibit TICs and HER2 in AI-resistant cells and tumors. Tretinoin erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 Modulation of cell viability and HER2 expression were assessed in AI-resistant cells treated with ATRA + ENT. Tretinoin erb-b2 receptor tyrosine kinase 2 Homo sapiens
4 Treatment with ATRA + ENT reduced HER2 expression and viability (P < 0.001) in AI-resistant cells, as well as decreased SP (P < 0.0001), mammosphere formation (P < 0.01), and expression of TIC molecular markers (P < 0.01) in LTLT-Ca. Tretinoin erb-b2 receptor tyrosine kinase 2 Homo sapiens